A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer

American Journal of Epidemiology

Volumn 178, Issue 8, 2013, Pages 1256-1264

  Poole, Elizabeth M ^a   Lee, I Min ^a   Ridker, Paul M ^a   Buring, Julie E ^a   Hankinson, Susan E ^a   Tworoger, Shelley S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

C reactive protein; interleukin 6; ovarian cancer; tumor necrosis factor receptor 2

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; UNCLASSIFIED DRUG;

BIOMARKER; CANCER; DATA ACQUISITION; DISEASE INCIDENCE; HEALTH RISK; META-ANALYSIS; PROTEIN; SAMPLING; TUMOR; WOMENS HEALTH;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); NURSE; OVARY CARCINOMA; PRIMARY PREVENTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; VITAMIN SUPPLEMENTATION;

C-REACTIVE PROTEIN; INTERLEUKIN 6; OVARIAN CANCER; TUMOR NECROSIS FACTOR Α RECEPTOR 2;

AGED; C-REACTIVE PROTEIN; FEMALE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885803062     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwt098     Document Type: Article

References (54)

1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011.
2. Fleming JS, Beaugie CR, Haviv I, et al. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol. 2006;247(1-2):4-21. (Pubitemid 43277703)
3. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999; 91(17):1459-1467. (Pubitemid 29424550)
4. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303-314.
5. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413-437.
6. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand. 2004;83(9):783-795. (Pubitemid 39179432)
7. Moorman PG, Schildkraut JM, Calingaert B, et al. Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control. 2002;13(9):807-811. (Pubitemid 35305199)
8. Pelucchi C, Galeone C, Talamini R, et al. Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies. Am J Obstet Gynecol. 2007;196(1):83.e1-83.e7.
9. Terry KL, Titus-Ernstoff L, McKolanis JR, et al. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(1):30-35. (Pubitemid 46174260)
10. Shacter E,Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park). 2002;16(2):217-226, 229.
11. Ziegler J. Cancer and arthritis share underlying processes. J Natl Cancer Inst. 1998;90(11):802-803. (Pubitemid 28280541)
12. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89(9):763-771. (Pubitemid 34633846)
13. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol. 2003;41(4 suppl S):37S-42S.
14. Maccio A, Lai P, Santona MC, et al. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998; 69(3):248-252. (Pubitemid 28289968)
15. Hefler LA, Concin N, Hofstetter G, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008;14(3):710-714. (Pubitemid 351231151)
16. McSorley MA, Alberg AJ, Allen DS, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 2007;109(4):933-941. (Pubitemid 46559083)
17. Lundin E, Dossus L, Clendenen T, et al. C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy). Cancer Causes Control. 2009;20(7): 1151-1159.
18. Toriola AT, Grankvist K, Agborsangaya CB, et al. Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study. Ann Oncol. 2011; 22(8):1916-1921.
19. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6): 448-454. (Pubitemid 29084777)
20. SchroderW, Ruppert C, Bender HG. Concomitant measurements of interleukin-6 (IL-6) in serum and peritoneal fluid of patients with benign and malignant ovarian tumors. Eur J Obstet Gynecol Reprod Biol. 1994;56(1):43-46.
21. Darai E, Detchev R, Hugol D, et al. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod. 2003;18(8):1681-1685. (Pubitemid 36958050)
22. Tempfer C, Zeisler H, Sliutz G, et al. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol. 1997;66(1):27-30. (Pubitemid 27329303)
23. Moradi MM, Carson LF,Weinberg B, et al. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer. 1993;72(8):2433-2440. (Pubitemid 23299609)
24. van der Zee AG, de Cuyper EM, Limburg PC, et al. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer. 1995;75(4):1004-1009.
25. Plante M, Rubin SC,Wong GY, et al. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer. 1994;73(7):1882-1888. (Pubitemid 24101966)
26. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994;43(11):1271-1278.
27. Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(5): 799-810.
28. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334(26):1717-1725. (Pubitemid 26193625)
29. Hankinson SE,Willett WC, Michaud DS, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1999; 91(7):629-634. (Pubitemid 29194050)
30. Tworoger SS, Sluss P, Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res. 2006;66(4):2476-2482.
31. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: theWomen's Health Study: a randomized controlled trial. JAMA. 2005;294(1):47-55. (Pubitemid 41002838)
32. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294(1):56-65. (Pubitemid 41002839)
33. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293-1304.
34. Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem. 2001;47(3):418-425. (Pubitemid 32222454)
35. Pischon T, Hankinson SE, Hotamisligil GS, et al. Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes Res. 2003;11(9):1055-1064. (Pubitemid 41151582)
36. Pai JK, Curhan GC, Cannuscio CC, et al. Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. Clin Chem. 2002;48(10):1781-1784.
37. Fernandez-Real JM, Broch M, RicartW, et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes. 1998;47(11):1757-1762. (Pubitemid 28476250)
38. Rosner B. Percentage points for a generalized ESD manyoutlier procedure. Technometrics. 1983;25(2):165-172. (Pubitemid 13540616)
39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. (Pubitemid 17189972)
40. Poole EM, Merritt MA, Jordan SJ, et al. Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. Cancer Epidemiol Biomarkers Prev. 2013; 22(3):429-437.
41. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145(1):21-29. (Pubitemid 46780601)
42. Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326-333. (Pubitemid 41043776)
43. Schulze MB, Hoffmann K, Manson JE, et al. Dietary pattern, inflammation, and incidence of type 2 diabetes in women. Am J Clin Nutr. 2005;82(3):675-715.
44. Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009;20(1): 15-26.
45. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27(13):2217-2224.
46. Hefler-Frischmuth K, Hefler LA, Heinze G, et al. Serum C-reactive protein in the differential diagnosis of ovarian masses. Eur J Obstet Gynecol Reprod Biol. 2009;147(1): 65-68.
47. Blum CA, Muller B, Huber P, et al. Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women. J Clin Endocrinol Metab. 2005;90(6):3230-3235. (Pubitemid 41014280)
48. Capobianco G, de Muro P, Cherchi GM, et al. Plasma levels of C-reactive protein, leptin and glycosaminoglycans during spontaneous menstrual cycle: differences between ovulatory and anovulatory cycles. Arch Gynecol Obstet. 2010;282(2): 207-213.
49. Puder JJ, Blum CA, Mueller B, et al. Menstrual cycle symptoms are associated with changes in low-grade inflammation. Eur J Clin Invest. 2006;36(1):58-64.
50. Wander K, Brindle E, O'Connor KA. C-reactive protein across the menstrual cycle. Am J Phys Anthropol. 2008;136(2): 138-146. (Pubitemid 351742812)
51. Bouckaert PX, Evers JL, Doesburg WH, et al. Patterns of changes in proteins in the peritoneal fluid of women during the periovulatory phase of the menstrual cycle. J Reprod Fertil. 1986;77(2):329-336. (Pubitemid 16075388)
52. Dobrzycka B, Terlikowski SJ, Garbowicz M, et al. Tumor necrosis factor-alpha and its receptors in epithelial ovarian cancer. Folia Histochem Cytobiol. 2009;47(4): 609-613.
53. Dobrzycka B, Terlikowski SJ, Kowalczuk O, et al. Circulating levels of TNF-alpha and its soluble receptors in the plasma of patients with epithelial ovarian cancer. Eur Cytokine Netw. 2009;20(3):131-134.
54. Kulbe H, Chakravarty P, Leinster DA, et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012;72(1):66-75.